Document is current

Article History

First Online: 31 October 2022

Competing interests

: R.M. reports institutional research payments from Abbott, Abiomed, Alleviant Medical, AM-Pharma, Amgen, Applied Therapeutics, Arena, AstraZeneca, AtriCure, Bayer, Biosensors, Biotronik, Boston Scientific, Bristol-Myers Squibb, CardiaWave, CeloNova, Chiesi, Concept Medical, CSL Behring, Cytosorbents, Daiichi Sankyo, Element Science, Faraday, Humacyte, Idorsia, Janssen, Magenta, Medtronic, Novartis, OrbusNeich, PhaseBio, Philips, Pi-Cardia, RenalPro, RM Global, Shockwave, Vivasure and Zoll; personal fees from Cine-Med Research, Novartis and WebMD; and equity (<1%) in Applied Therapeutics, Elixir Medical, Stel and ControlRad (spouse). R.M. is also a member of the AMA scientific advisory board, the ACC board of trustees, and the SCAI Women in Innovations Committee; is an associate editor for <i>Journal of the American Medical Association</i>; and is Cardiovascular Research Foundation faculty (no fee). B.V. declares no competing interests.